Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01462071 · ClinicalTrials.gov registry record

Red Blood Cell Lifespan

A clinical trial, sponsored by Renal Research Institute.

Terminated
Registry status
58
Enrollment target

NCT01462071: Clinical Trial study, sponsored by Renal Research Institute.

NCT01462071 is a clinical trial that was terminated before completion, run by Renal Research Institute. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01462071 was terminated before completion, sponsored by Renal Research Institute.

TERMINATED
Registry status
58 participants
Enrollment target

Study Summary

Background: A low amount of red blood cells in the blood of patients with limited kidney function is a well known problem. Besides the lack of substances in the blood like iron or erythropoietin the shortened survival of red blood cells leads to the low red blood cell count. Red blood cells of patients on kidney replacement therapy (dialysis) die earlier than those of healthy persons. They live only about 70 days compared to 120 days in healthy humans. Today little is known about the causes for the shorter survival of the red blood cells in patients on dialysis. Because inflammation leads to a shorter life of the red blood cells in people suffering from several diseases leading to inflammation we would like to learn about the role of inflammation in the shortened life of red blood cells of dialysis patients. When red blood cells are dying the content is broken down to several substances. One of these substances is the gas carbon monoxide (CO). The carbon monoxide is exhaled with the breath. The more red blood cells die the more CO is exhaled. That's why we can calculate the lifespan of the red blood cells when we measure the amount of CO in breath at the same time as the red blood cell count in the blood. Aim of the study: We aim to learn about the influence of inflammation of on red blood cell survival in dialysis patients. To look for factors with effect on inflammation or red blood cell survival, for example type of dialysis access, medication or kind of dialysis treatment. Study procedures: Over the course of the 18 month study, 6 observational assessments will take place. If the patient experiences a situation with increased inflammation during the study period (for example any kind of infection or intervention) up to two more study visits will take place. Each study visit will include blood sampling, performed without the need for an extra needle stick, and a breath sampling in order to calculate the red blood survival and to measure markers for inflamma

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2008-05
Est. Completion 2013-03
Renal Research Institute

14 total trials

Why NCT01462071 stopped before completion

NCT01462071 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01462071 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01462071 about?

NCT01462071 is a clinical study titled "Red Blood Cell Lifespan". Background: A low amount of red blood cells in the blood of patients with limited kidney function is a well known problem. Besides the lack of substances in the blood like iron or erythropoietin the shortened survival of red blood cells leads to the low red blood cell count. Red blood cells of pati...

What is the current status of trial NCT01462071?

This trial is currently terminated. The enrollment target is 58 participants. The study started on 2008-05. Estimated completion is 2013-03.

Who is sponsoring clinical trial NCT01462071?

This trial is sponsored by Renal Research Institute, which has 14 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01462071, the US trial registry maintained by the National Library of Medicine. NCT01462071 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.